The oncology market is surging despite a decline in routine screenings

A new report from IQVIA reveals the current challenges — and promise — in cancer drug R&D.

By Kelly Bilodeau • June 28, 2022

With abortion access restricted across the U.S., a new diagnostic aims to eliminate birth control's pain points

The hormonal and genetic test developed by Adyn is designed to predict and prevent adverse birth control side effects.

By Karissa Waddick • June 28, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

'Nobel Prize of pharma' helps put Huma's digital health platform on the global map

The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.

By Kim Ribbink • June 23, 2022

#DIA2022: Building 'guardrails' in the FDA's accelerated approval program

Regulatory experts weigh in on ways to enhance the controversial drug approval approach.

By Karissa Waddick • June 21, 2022

The public health sleuth

In her decades-long career, Mary Pittman, CEO of the Public Health Institute, has seen — and helped solve — one public health mystery after another.

By Alexandra Pecci • June 21, 2022

Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience

An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

By Kim Ribbink • June 16, 2022

A patient-funded ALS drug offers hope where few treatments exist

Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.

By Kelly Bilodeau • June 15, 2022

A combo of precision meds and diagnostics could disrupt mental healthcare

HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.

By Kelly Bilodeau • June 8, 2022

After losing her daughter to a rare disease, Sharon King is looking to rewrite the playbook of drug development

The communications pro is lending her community-building, storytelling expertise to the Bespoke Gene Therapy Consortium.

By Alexandra Pecci • June 7, 2022

Pharma giants take on Appalachian cancer rates in newest screening initiative

AstraZeneca and Bristol Myers Squibb are teaming up with the nonprofit Association of Community Cancer Centers to increase lung cancer screening in rural Appalachia for the long haul.

By Karissa Waddick • June 7, 2022

Aduhelm's Medicare woes leave questions about lofty premiums

A single drug’s effect on the premiums that Medicare beneficiaries pay is raising questions about how these levels are set and what factors play a part.

By Kelly Bilodeau • June 2, 2022

Pharmas can be 'more than medicine' by focusing on preventative care

Why pharma companies are changing their tack to become more than the products they sell.

By Michael Gibney • May 24, 2022

The UK-based company that's striving to overcome the limitations of T cell receptor innovation

Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.

By Kim Ribbink • May 23, 2022

3 things medical communications can learn from sales training experts

Medical communications is moving toward more modern approaches that can make critical information more engaging and better able to "stick".

May 23, 2022

A potential COVID-19 EUA could turn this small biotech into a household name

Veru’s CEO discusses the impact of the upcoming FDA decision on its treatment targeting severely ill COVID-19 patients.

By Meagan Parrish • May 19, 2022

Jumping into pharma with big plans at a small company

SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.

By Alexandra Pecci • May 17, 2022

BriOri BioTech sets the stage for the comeback of Vioxx

With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.

By Kelly Bilodeau • May 17, 2022

Are digital DCTs the answer for rare diseases?

How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.

By Kim Ribbink • May 16, 2022

After 40 years, researchers discover new frontiers in the fight against HIV

Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.

By Karissa Waddick • May 16, 2022

A better approach to boosting patient engagement

GoodRx solutions help biopharma brands overcome common barriers & increase patient engagement.

May 16, 2022

Why 'soft' skills matter in the new era of leadership

Standout leaders honored by the Healthcare Businesswomen's Association discuss the rising value of the interpersonal approach.

By Taren Grom • May 12, 2022

Woman of the Week: AiCure's Michelle Marlborough

As chief product officer at AiCure, Michelle Marlborough is focused on solving tough patient challenges through technology.

By Taren Grom • May 11, 2022

It's time to acknowledge access as a prescribing barrier

A new survey reveals how red tape limits patient access to doctor-preferred specialty drugs. 

By Karissa Waddick • May 11, 2022

FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have

New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.

By Kelly Bilodeau • May 10, 2022

Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

By Taren Grom • May 9, 2022